Journals / Türk Yoğun Bakım Dergisi / 2021 / Cilt: 19 - Sayı: 1

Association of Charlson Comorbidity and Pneumonia Severity Indices with Mortality in Patients with Coronavirus Disease-2019 in the Intensive Care Unit

Yoğun Bakım Ünitesinde Takip Edilen Koronavirüs Hastalığı-2019 Hastalarında Charlson Komorbidite İndeksi ve Pnömoni Şiddet İndeksinin Mortalite ile İlişkisi

Pages
33–41
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the correlation analysis performed to determine the relationship between CCI and PSI, a bidirectional and strong correlation was found between CCI and PSI (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Risk factors affecting mortality in the coronavirus disease-2019 (COVID-19) pandemic, which emerged in Wuhan, China and affected the whole world, are yet to be clearly determined.
📊
Key Findings & Data:This study aimed to determine the relation between CCI, indicating comorbidity burden in COVID-19 infection, and PSI, indicating disease severity, and their relationship with mortality.
💡
Conclusion & Impact:In the correlation analysis performed to determine the relationship between CCI and PSI, a bidirectional and strong correlation was found between CCI and PSI (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Risk factors affecting mortality in the coronavirus disease-2019 (COVID-19) pandemic, which emerged in Wuhan, China and affected the whole world, are yet to be clearly determined. Assessment of Charlson comorbidity index (CCI) and pneumonia severity index (PSI) can assist clinicians in identifying patients at high risk of mortality. This study aimed to determine the relation between CCI, indicating comorbidity burden in COVID-19 infection, and PSI, indicating disease severity, and their relationship with mortality. Materials and Methods: This was a retrospective cohort study conducted by accessing demographic, clinical and laboratory data from the electronic medical records of 214 patients diagnosed with COVID-19. The patients were followed up in the intensive care unit of University of Health Sciences Turkey, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital between March 10, 2020 and June 1, 2020. Results: Patients were divided into two groups i.e., survivors (n=109; 50.9%) and those with mortality (n=105; 49.1%). A one point increase in CCI was determined to increase the mortality probability by 32% [odds ratio (OR): 1,324, 95% confidence interval (CI): 1,178-1,488]. On the other hand, a one-point increase in PSI increased the mortality possibility by 2% (OR: 1,020, 95% CI: 1,012-1,0,27). In the correlation analysis performed to determine the relationship between CCI and PSI, a bidirectional and strong correlation was found between CCI and PSI (p

Özet

Amaç: Çin’in Wuhan kentinde ortaya çıkan ve tüm dünyayı etkisi altına alan koronavirüs hastalığı-2019 (COVID-19) pandemisinde mortaliteyi etkileyen risk faktörleri henüz açıkça belirlenmemiştir. Mortalite riski yüksek olan hastaların belirlenmesinde Charlson komorbidite indeksi (CCI) ve pnömoni şiddet indeksi (PSI) değerlendirmesi klinisyenlere yardımcı olabilir. Bu çalışmanın amacı, COVID-19 enfeksiyonunda komorbidite yükünü gösteren CCI ile hastalık şiddetini gösteren PSI arasındaki ilişkinin ve mortalite ile ilişkisinin belirlenmesidir. Gereç ve Yöntem: Bu araştırma, 10 Mart 2020-1 Haziran 2020 tarihleri arasında Sağlık Bilimleri Üniversitesi, İstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi’nin Yoğun Bakım Ünitesi’nde takip edilen COVID-19 tanısı almış 214 hastanın elektronik medikal kayıtlardan demografik, klinik ve laboratuvar verilerine ulaşılarak değerlendirilmesi ile retrospektif kohort olarak gerçekleştirilmiştir. Bulgular: Hastalar; hayatta kalan (n=109; %50,9) ve mortalite gelişenler (n=105; %49,1) olmak üzere iki gruba ayrıldı. CCI’da bir puanlık artışın mortalite olasılığını %32 artırdığı belirlendi [olasılık oranı (OR): 1.324 %95 güven aralığı (GA): 1.178-1.488]. PSI’da bir puanlık artışın mortalite olasılığını %2 artırdığı belirlendi. (OR: 1.020; %95 GA: 1.012-1.0.27). CCI ve PSI arasındaki ilişkiyi belirlemek için yapılan korelasyon analizinde CCI ile PSI arasında çift yönlü ve kuvvetli bir korelasyon olduğu belirlendi (p

🔖

Cite This Article

AŞAR, S., SABAZ, M. S. (2022). Association of Charlson Comorbidity and Pneumonia Severity Indices with Mortality in Patients with Coronavirus Disease-2019 in the Intensive Care Unit. Türk Yoğun Bakım Dergisi, Cilt: 19 - Sayı: 1, 33–41. https://ajindex.com/articles/643419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Del Rio C, Malani PN. COVID-19-New Insights on a Rapidly Changing Epidemic. JAMA 2020;323:1339-40
  2. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 11 March 2020
  3. Dünya Sağlık Örgütü Koronavirüs hastalığı (COVID-19) pandemisi 2020. Bağlantı adresi: https://www.who. int/emergencies/diseases/novelcoronavirus- 2019. Erişim tarihi: 20 Kasım 2020
  4. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: towards controlling of a pandemic. Lancet 2020;395:1015-8
  5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID- 19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42
  6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20
  7. FitzGerald GA. Misguided drug advice for COVID-19. Science 2020;367:1434
  8. Tuty Kuswardhani RA, Henrina J, Pranata R, Anthonius Lim M, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:2103-9
  9. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China Medical Treatment Expert Group for COVID- 19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547
  10. Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart 2014;100:288-94
  11. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
  12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
  13. Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 2020;288:469-76
  14. Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why Summary Comorbi